NCT00023712 2019-07-30
Bortezomib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Phase 2 Completed
Clinical Trials
19 trialsNCT00041080 2019-07-30
Tamoxifen Compared With Thalidomide in Treating Women With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT00022659 2019-07-24
Bevacizumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00025155 2019-07-24
Ixabepilone in Treating Patients With Ovarian Epithelial or Primary Peritoneal Cancer That Has Not Responded to Previous Chemotherapy
National Cancer Institute (NCI)
Phase 2 Completed
NCT00053365 2019-07-24
Irofulven in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00113373 2019-07-24
Lapatinib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00429793 2019-07-24
Temsirolimus in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00993616 2019-07-23
Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin
National Cancer Institute (NCI)
Phase 2 Completed
NCT00436501 2019-02-26
VEGF Trap and Docetaxel in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00278343 2018-08-29
Cediranib Maleate in Treating Patients With Persistent, Recurrent, or Refractory Advanced Ovarian Epithelial, Peritoneal Cavity, or Fallopian Tube Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00334893 2017-11-29
Eribulin Mesylate in Treating Patients With Recurrent Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT01681368 2017-05-30
Birinapant for Advanced Ovarian, Fallopian Tube, and Peritoneal Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT00182767 2016-03-10
Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00390234 2015-12-07
Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00059787 2015-12-01
Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00313612 2015-11-27
Oxaliplatin and Topotecan in Advance Ovarian Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00275028 2015-11-09
AZD2171 in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT01200797 2015-05-25
SJG-136 in Treating Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer That Did Not Respond to Previous Treatment With Cisplatin or Carboplatin
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00083122 2014-05-21
Cisplatin and Flavopiridol in Treating Patients With Advanced Ovarian Epithelial Cancer or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Phase 2 Completed